Our Questions

Getting to the ROOT of our Lock down Virus Narrative.

We want to know how, who, where, when an document it here.


Get involved

Dr. Peter Daszak. 2015 published Feb 12, 2016 

"We need to increase public understanding of the need for medical counter measures such as a pan corona virus vaccine. A key driver is the media and the economics will follow the hype, we need to use that hype to our advantage to get to the real issues, investors will respond if they see profit at the end of the process."

Independent Investigator / Spike Proteins

Ralph Barrak you can make a lot of money off of this.

73 Patents on All "NOVEL" / 7279327 Recombinated nature of lung virus transferred in 2017-2018 from US Chapel of Health - US Govt Paid for Research 

Do something

Dr.'s talk about the issues

The last 16 months have been a rollercoaster of fears and facts, and we have seen the narrative behind COVID-19 change constantly, it was novel after all, what could we expect?
Dr. Reiner Fuellmich who has been leading the charge on exposing the true information surrounding COVID-19 recently hosted Dr. David Martin, a professional analyst who has shared some disturbing information. His evidence appears very compelling and credible, and I have fact checked some of the patents he has identified. It’s clear COVID-19 was never a novel (new) virus.
Watch this interview in full, hear the testimony of Dr. David Martin and the patents he’s analysed over the last many years. All publicly available going back to 1999 showing the Novel Coronavirus was well known for two decades. He explains his credentials and provides many quotes about how this present outbreak was probably engineered.
It was a surprise to me that we knew about this back in 2000 following a patent application by Miller, Klepfer, Reid and Jones Jan 28 2000 US patent 6372224.
If you are as concerned as I am, I encourage you to share this video, tag your friends, family, and neighbours, encourage them to examine the narrative versus the emerging evidence and put an end to these lockdowns.
#ONPoli #CDNPoli #NoMoreLockdowns #WeMustResist #WeAreLivingALie
See Less


Learn more

 
 

Indian Investigation 

Following the money trail that our present virus problems have been manipulated by the US CDC and Chinese. More investigations will be hopefully taken up as Gain of Function Research had been continued and financed by US Interest in China. 

Discover more

Methods for producing recombinant coronavirus

Abstract

A helper cell for producing an infectious, replication defective, coronavirus (or more generally nidovirus) particle cell comprises (a) a nidovirus permissive cell; (b) a nidovirus replicon RNA comprising the nidovirus packaging signal and a heterologous RNA sequence, wherein the replicon RNA further lacks a sequence encoding at least one nidovirus structural protein; and (c) at least one separate helper RNA encoding the at least one structural protein absent from the replicon RNA, the helper RNA(s) lacking the nidovirus packaging signal. The combined expression of the replicon RNA and the helper RNA in the nidovirus permissive cell produces an assembled nidovirus particle which comprises the heterologous RNA sequence, is able to infect a cell, and is unable to complete viral replication in the absence of the helper RNA due to the absence of the structural protein coding sequence in the packaged replicon. Compositions for use in making such helper cells, along with viral particles produced from such cells, compositions of such viral particles, and methods of making and using such viral particles, are also disclosed.


SUMMARY OF THE INVENTION
A first aspect of the present invention is a helper cell for producing an infectious, replication defective, nidovirus particle. The helper cell comprises (a) a nidovirus permissive cell (e.g., a cell permissive of replication but not necessarily infection); (b) a nidovirus replicon RNA comprising the nidovirus packaging signal and a heterologous RNA sequence, wherein the replicon RNA further lacks a sequence encoding at least one nidovirus structural protein (e.g., lacks one, two, three, four or all); and (c) at least one separate helper RNA (e.g., one, two, three, four, etc. separate helper RNAs) encoding the at least one structural protein absent from the replicon RNA, the helper RNA(s) lacking the nidovirus packaging signal. The combined expression of the replicon RNA and the helper RNA in the nidovirus permissive cell produces an assembled nidovirus particle which comprises the heterologous RNA sequence, is able to infect a cell, and is unable to complete viral replication in the absence of the helper RNA due to the absence of the structural protein coding sequence in the packaged replicon.
Example nidoviruses that may be used to carry out the present invention include members of the familes Coronaviridae and Arteriviridae. Currently preferred are the coronaviruses.
In some embodiments, the replicon RNA further comprises a sequence encoding at least one of the nidovirus structural proteins (for example, the M, N, and/or S genes). In other embodiments, the replicon RNA lacks all of the nidovirus structural proteins. Thus in some embodiments, the helper RNA contains (or helper RNAs contain) at least one gene encoding a structural protein, such as the E, M, N, and/or S genes.
In certain preferred embodiments, the replicon RNA and/or the helper RNA contains at least one attenuating gene order rearrangement among the 3A, 3B, HP, S, E, M and N genes.
In certain embodiments, the helper RNA and/or the replicon RNA may include a promoter(in the helper RNA, to drive expression of the appropriate helper gene or genes; in the replicon RNA, to drive expression of the coronavirus genes or the heterologous genes (which may be driven by the same or a different promoter). In certain embodiments of the invention, the helper cell may include a heterologous DNA encoding the replicon RNA, and/or a heterologous DNA encoding the helper RNA, with the replicon RNA and/or the helper RNA being transcribed from the corresponding DNA in the permissive cell.
A further aspect of the present invention is a method of making infectious, replication defective, nidovirus particles, comprising: providing a helper cell as described above, producing the nidovirus particles in the helper cell; and then collecting the nidovirus particles from the helper cell. The replicon RNA and the at least one separate helper RNA are stably or transiently introduced into the helper cell by any suitable means, such as electroporation of the RNA into the cell, introduction of DNA into the cell as noted above, etc.
A still further aspect of the invention is infectious nidovirus particles containing a heterologous RNA within a replicon RNA as described above. Such particles may be produced by the methods described above. In certain preferred embodiments the present invention provides a composition comprising a population of infectious, replication defective, nidovirus particles, wherein each particle comprises a nidovirus replicon RNA, wherein the replicon RNA comprises a nidovirus packaging signal and one or more heterologous RNA sequences, wherein the replicon RNA further lacks a sequence encoding at least one nidovirus structural protein, and wherein the population contains no detectable replication-competent nidovirus particles as determined by passage on nidovirus permissive cells (e.g., cells permissive of infection and replication) in culture. As previously, the replicon RNA may further comprise a sequence encoding at least one nidovirus structural protein. Also as previously, the replicon RNA may contain at least one attenuating gene order rearrangement among the 3a, 3b, Hp, S, E, M and N genes.
Available On Line